

Lawrence B Schwartz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4492596/publications.pdf>

Version: 2024-02-01

109
papers

9,484
citations

41627

51
h-index

42259

96
g-index

110
all docs

110
docs citations

110
times ranked

6139
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1010-1017.e10.	1.5	38
2	Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1999-2012.e6.	2.0	35
3	Heritable risk for severe anaphylaxis associated with increased β -tryptase encoding germline copy number at TPSAB1. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 622-632.	1.5	137
4	Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 411.	1.8	21
5	Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3918-3928.	2.0	33
6	COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2139-2144.	2.0	31
7	Clinical relevance of inherited genetic differences in human tryptases. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 638-647.	0.5	30
8	Mast Cell Activation During Suspected Perioperative Hypersensitivity: A Need for Paired Samples Analysis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3051-3059.e1.	2.0	13
9	Use and Interpretation of Acute and Baseline Tryptase in Perioperative Hypersensitivity and Anaphylaxis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2994-3005.	2.0	45
10	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. <i>HemaSphere</i> , 2021, 5, e646.	1.2	128
11	New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019. <i>Leukemia and Lymphoma</i> , 2020, 61, 1075-1083.	0.6	11
12	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. <i>Theranostics</i> , 2020, 10, 10743-10768.	4.6	107
13	Fluvastatin Induces Apoptosis in Primary and Transformed Mast Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 374, 104-112.	1.3	6
14	Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 125, 334-340.e1.	0.5	4
15	Clinical Approach to a Patient with Elevated Serum Tryptase: Implications of Acute Versus Basally Elevated Levels. , 2020, , 35-54.		3
16	Impact of naturally forming human β -tryptase heterotetramers in the pathogenesis of hereditary β -tryptasemia. <i>Journal of Experimental Medicine</i> , 2019, 216, 2348-2361.	4.2	85
17	AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 883-896.	1.5	72
18	An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma. <i>Cell</i> , 2019, 179, 417-431.e19.	13.5	76

#	ARTICLE	IF	CITATIONS
19	Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1793-1802.e2.	2.0	58
20	Paired acuteâ€baseline serum tryptase levels in perioperative anaphylaxis: An observational study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1157-1165.	2.7	49
21	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1125-1133.e1.	2.0	150
22	Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: AÂWork Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 880-893.	1.5	50
23	Clinical communication: systemic capillary leak syndrome due to mast cell activation?. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 122, 428-429.	0.5	0
24	IgE-mediated mast cell activation promotes inflammation and cartilage destruction in osteoarthritis. <i>ELife</i> , 2019, 8, .	2.8	74
25	Dual functionality of Î²-tryptase protomers as both proteases and cofactors in the active tetramer. <i>Journal of Biological Chemistry</i> , 2018, 293, 9614-9628.	1.6	13
26	Human mast cells present antigen to autologous CD4+ T cells. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 311-321.e10.	1.5	52
27	Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2108.	3.8	174
28	Mast cell activation syndrome: Importance of consensus criteria and call for research. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1008-1010.	1.5	27
29	Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 464-468.e3.	0.5	40
30	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , 2017, 77, 1261-1270.	0.4	210
31	A Multiparametric Model for Mapping Cellularity in Glioblastoma Using Radiographically Localized Biopsies. <i>American Journal of Neuroradiology</i> , 2017, 38, 890-898.	1.2	90
32	Chronic Idiopathic Urticaria: Systemic Complaints and Their Relationship with Disease and Immune Measures. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1314-1318.	2.0	49
33	Fatal anaphylaxis caused by gadolinium due to beta-tryptaseâ€induced hemorrhagic diathesis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1433-1434.	2.0	9
34	A humanized mouse model of anaphylactic peanut allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 314-322.e9.	1.5	54
35	Regulation of Reactive Oxygen Species and the Antioxidant Protein DJ-1 in Mastocytosis. <i>PLoS ONE</i> , 2016, 11, e0162831.	1.1	9
36	Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. <i>Nature Genetics</i> , 2016, 48, 1564-1569.	9.4	279

#	ARTICLE	IF	CITATIONS
37	Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. <i>World Allergy Organization Journal</i> , 2016, 9, 7.	1.6	124
38	Anaphylaxis and Its Management. , 2016, , 651-671.		0
39	Presence or Absence of Elevated Acute Total Serum Tryptase by Itself Is Not a Definitive Marker for an Allergic Reaction. <i>Anesthesiology</i> , 2015, 122, 713-714.	1.3	34
40	Refractory intraoperative hypotension with elevated serum tryptase. <i>Asia Pacific Allergy</i> , 2015, 5, 47-50.	0.6	6
41	Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 262-271.e2.	1.5	51
42	Anaphylaxis in America: A national physician survey. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 830-833.	1.5	31
43	Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder. <i>Haematologica</i> , 2015, 100, 300-307.	1.7	60
44	A Simple, Sensitive and Safe Method to Determine the Human β -Tryptase Genotype. <i>PLoS ONE</i> , 2014, 9, e114944.	1.1	9
45	Contribution of Mast Cell-Derived Interleukin-1 β to Uric Acid Crystal-Induced Acute Arthritis in Mice. <i>Arthritis and Rheumatology</i> , 2014, 66, 2881-2891.	2.9	59
46	Basophils are elevated in nasal polyps of patients with chronic rhinosinusitis without aspirin sensitivity. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1759-1763.	1.5	80
47	Anaphylaxis in America: The prevalence and characteristics of anaphylaxis in the United States. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 461-467.	1.5	319
48	Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1471-1474.	1.5	110
49	Increased circulating levels of neurotrophins and elevated expression of their high-affinity receptors on skin and gut mast cells in mastocytosis. <i>Blood</i> , 2013, 122, 1779-1788.	0.6	31
50	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. <i>Blood</i> , 2013, 121, 2393-2401.	0.6	122
51	Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal. <i>International Archives of Allergy and Immunology</i> , 2012, 157, 215-225.	0.9	513
52	Obesity is not linked to increased whole-body mast cell burden in children. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 1164-1166.e4.	1.5	8
53	In Vitro Desensitization of Human Skin Mast Cells. <i>Journal of Clinical Immunology</i> , 2012, 32, 150-160.	2.0	20
54	Total tryptase levels indicate risk for systemic reactions to rush immunotherapy and mast cell activation. <i>Annals of Allergy, Asthma and Immunology</i> , 2011, 106, 342-343.e6.	0.5	8

#	ARTICLE	IF	CITATIONS
55	Processing of Human Protryptase in Mast Cells Involves Cathepsins L, B, and C. <i>Journal of Immunology</i> , 2011, 187, 1912-1918.	0.4	26
56	Promiscuous Processing of Human \hat{I}^{\pm}/\hat{I}^2 -Protryptases by Cathepsins L, B, and C. <i>Journal of Immunology</i> , 2011, 186, 7136-7143.	0.4	18
57	Tryptase Is Not Cleared by the Kidneys into the Urine. <i>International Archives of Allergy and Immunology</i> , 2010, 152, 28-31.	0.9	18
58	Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 719-726.e4.	1.5	128
59	Current strategies in the management of hypereosinophilic syndrome, including mepolizumab. <i>Current Medical Research and Opinion</i> , 2010, 26, 1933-1946.	0.9	15
60	Assessing anaphylactic risk? Consider mast cell clonality. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 687-688.	1.5	53
61	Mast Cells. , 2009, , 31-52B.		0
62	Mast Cells and Basophils. , 2009, , 157-193.		0
63	TGF- \hat{I}^2 1 Attenuates Mediator Release and De Novo Kit Expression by Human Skin Mast Cells through a Smad-Dependent Pathway. <i>Journal of Immunology</i> , 2008, 181, 7263-7272.	0.4	40
64	Generation of Anaphylatoxins by Human \hat{I}^2 -Tryptase from C3, C4, and C5. <i>Journal of Immunology</i> , 2008, 180, 6307-6316.	0.4	92
65	Omalizumab Reverses the Phenotypic and Functional Effects of IgE-Enhanced Fc \hat{I}^{μ} RI on Human Skin Mast Cells. <i>Journal of Immunology</i> , 2007, 179, 1353-1361.	0.4	70
66	Active monomers of human \hat{I}^2 -tryptase have expanded substrate specificities. <i>International Immunopharmacology</i> , 2007, 7, 1900-1908.	1.7	24
67	Risk assessment in anaphylaxis: Current and future approaches. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, S2-S24.	1.5	237
68	Tryptase haplotype in mastocytosis: Relationship to disease variant and diagnostic utility of total tryptase levels. <i>Clinical Immunology</i> , 2007, 123, 268-271.	1.4	40
69	Diagnostic Value of Tryptase in Anaphylaxis and Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2006, 26, 451-463.	0.7	376
70	Current Options in the Treatment of Mast Cell Mediator-Related Symptoms in Mastocytosis. <i>Inflammation and Allergy: Drug Targets</i> , 2006, 5, 61-77.	1.8	76
71	Evaluation of biologic activity of tryptase secreted from blast cells in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 897-906.	0.6	11
72	The B12 Anti-Tryptase Monoclonal Antibody Disrupts the Tetrameric Structure of Heparin-Stabilized \hat{I}^2 -Tryptase to Form Monomers That Are Inactive at Neutral pH and Active at Acidic pH. <i>Journal of Immunology</i> , 2006, 176, 3165-3172.	0.4	30

#	ARTICLE	IF	CITATIONS
73	Analysis of MC(T) and MC(TC) mast cells in tissue. <i>Methods in Molecular Biology</i> , 2006, 315, 53-62.	0.4	26
74	Surface CD88 functionally distinguishes the MCTC from the MCT type of human lung mast cell. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 1162-1168.	1.5	133
75	Human β -Tryptase:â€” Detection and Characterization of the Active Monomer and Prevention of Tetramer Reconstitution by Protease Inhibitors. <i>Biochemistry</i> , 2004, 43, 10757-10764.	1.2	35
76	Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and nonâ€” mast cell hematopoietic neoplasms. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 3-11.	1.5	157
77	Effect of sex and haplotype on plasma tryptase levels in healthy adults. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 48-51.	1.5	40
78	Expression of β -tryptase and β -tryptase by human basophils. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 113, 1086-1092.	1.5	97
79	Enumeration and Immunologic Characterization of Basophils in Normal Bone Marrow and Patients with Myeloproliferative Disorders.. <i>Blood</i> , 2004, 104, 4754-4754.	0.6	0
80	Effector cells of anaphylaxis: mast cells and basophils. <i>Novartis Foundation Symposium</i> , 2004, 257, 65-74; discussion 74-9, 98-100, 276-85.	1.2	15
81	Immunological characterization of A2B adenosine receptors in human mast cells. <i>Drug Development Research</i> , 2003, 58, 461-471.	1.4	16
82	Tryptase Precursors Are Preferentially and Spontaneously Released, Whereas Mature Tryptase Is Retained by HMC-1 Cells, Mono-Mac-6 Cells, and Human Skin-Derived Mast Cells. <i>Journal of Immunology</i> , 2003, 170, 5667-5673.	0.4	107
83	Association of Transient Dermal Mastocytosis and Elevated Plasma Tryptase Levels with Development of Adverse Reactions after Treatment of Onchocerciasis with Ivermectin. <i>Journal of Infectious Diseases</i> , 2002, 186, 1307-1313.	1.9	24
84	Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: Correlation with dermal mast-cell numbers and mast-cell tryptase. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 82-88.	1.5	52
85	Characterization of mast-cell tryptase-expressing peripheral blood cells as basophils. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 287-293.	1.5	67
86	Human mouse mast cell protease 7â€”like tryptase genes are pseudogenes. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 107, 315-321.	1.5	18
87	Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. <i>Blood</i> , 2001, 98, 2200-2209.	0.6	130
88	Human skinâ€”derived mast cells can proliferate while retaining their characteristic functional and protease phenotypes. <i>Blood</i> , 2001, 97, 2045-2052.	0.6	133
89	Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. <i>Leukemia Research</i> , 2001, 25, 553-562.	0.4	95
90	Diagnostic criteria and classification of mastocytosis: a consensus proposal. <i>Leukemia Research</i> , 2001, 25, 603-625.	0.4	1,020

#	ARTICLE	IF	CITATIONS
109	Mast cell numbers and histamine levels in synovial fluids from patients with diverse arthritides. Arthritis and Rheumatism, 1986, 29, 956-963.	6.7	124